A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229
Aberrant Motor Behavior in Dementia, Agitation
Chandler, Arizona, United States
View Trial DetailsNCT Number: NCT07309107
Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of [18F]flutemetamol.
Interested in participating?
Request Info18 year–99 year
All sexes
Observational
CHRU NANCY Brabois, nuclear medicine department, Vandœuvre-lès-Nancy, France
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Day one
Visual analysis of the cerebral [¹⁸F]flutemetamol PET images will be performed by two nuclear medicine specialists in a blinded manner, with a third reader acting as an arbitrator in case of disagreement, according to routine diagnostic criteria.
Contact information is provided by the study sponsor or research team.
Central Hospital, Nancy, France
Other
Impact of Deep Learning-Based Noise Reduction Algorithm on Visual Analysis and Centiloid Quantification in Reduced-Dose and, or Time Acquisition Amyloid PET Imaging
Acronym: DEEPAMY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06937229
Aberrant Motor Behavior in Dementia, Agitation
Chandler, Arizona, United States
View Trial DetailsNCT06862960
Alzheimer Disease, Brain Diseases
Fuzhou, Fujian, China
View Trial DetailsNCT06072963
Alzheimer Disease, Brain Diseases
Ramat Gan, Israel
View Trial DetailsNCT07721701
Alzheimer Disease, Arterial Occlusive Diseases
Aschaffenburg, Germany
View Trial Details